Sweet itch remains one of the most welfare-challenging chronic conditions in horses, and new developments in allergy immunotherapy and biologic treatments are expanding management options.
Sweet itch causes severe chronic welfare suffering that tests both horse welfare and owner commitment. The intensity of the pruritis during peak midge season is overwhelming — horses self-mutilate through rubbing that causes mane and tail hair loss, skin thickening, open wounds, and secondary infection. The management burden for owners is high — daily rugging, twice-daily repellent application, stabling adjustments, and wound care. Immunotherapy offers the prospect of addressing the hypersensitivity mechanism rather than managing its consequences. Early results from European immunotherapy trials are promising, and this treatment avenue represents the most significant advance in sweet itch management in decades. Development of equine biologic therapies could eventually provide relief comparable to dupilumab in human atopic dermatitis.